u/deleted_my_history

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

nothing in this board is legal advice

Spent an evening reading about small-molecule agonism at a peptide receptor.

Adding the standing caveat — unapproved, and research material is not for human use.

Disagree.

flair_enthusiast is right that milligram comparisons across classes tell you nothing.

Import rules are national and they distinguish between personal and commercial import, with different thresholds, documentation and consequences. A general answer is almost always wrong somewhere.

the phase 2 numbers were striking and they were also 48 weeks in a small population

Yes — histological endpoints are a far harder bar than the surrogate measures people are used to quoting.

research-use-only material is not approved for human use, full stop

lead times on unusual lines are the thing to confirm up front

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

nothing here is available as a prescription product, so read every thread with that in mind

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

This. Ordering from regional stock takes the entire question off the table, which is why it comes up in every one of these threads.

Same. Net peptide content is where the difference between the label and the vial actually shows up.

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

small molecule, not a peptide, and that changes everything about it

That is a phase 2 result being quoted as though the programme had reported.

Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.

Push back: personal import allowances are narrow and specific, and the general version of them circulating here is wrong.

Storage guidance that names a temperature, a state and a duration reflects actual stability work. Generic guidance usually reflects a template.

comparing reta phase 2 to sema phase 3 is comparing different things

Are you comparing against phase 3 numbers for something else? They are not comparable.

Which phase 2 arm are you quoting, and at what week?

Why regional stock keeps coming up in every thread on this board.

If the line you want is held in a warehouse in your own country, your order is a domestic shipment. There is no import event, no clearance stage and no notice to manage. That is not a workaround; it is a different transaction.

So the useful pre-order question is which lines a supplier actually holds regionally rather than drop-ships from origin. It is one email, the answer is usually a list, and for anybody who has spent a fortnight watching a tracking page it reframes the whole problem.

phase 2 data only, and people quote it like it is a label

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.